At the 30th general meeting of this association we reported the value of conducting a fundamental, methodological study of stellate ganglion insertion on the basis of clinical indications obtained from clinical results indicating that stellate ganglion insertion (hereafter referred to as SG insertion) on the affected side is appropriate for the treatment of the central sensory dis-turbances, especially numbness of the arms on the afflicted side, accompanying post cerebral apoplexy syndromes.
At this time we'd like to report, using cutaneous surface temperature as an index, the results of examinations of the inflnences exerted on circulatory fluctuation by SG insertion, from among our fundamental study of the functional mechanism of SG insertion.
The cutaneous surface temperature was measured using a Fujitsu made Infra-eye 150 thermograph. After the clothing from the upper half of the body was removed and the patient had rested in a sitting position for 20 minutes in a temperature-humieity controlled room, the body was monitored and from the picture obtained the cutaneous surface temperature at the 5 points used in this study, GB-14, LI-20, SI-18, _??__??_, and LI-14, measured.
There was no significant difference in the cutaneous surface temperatures at the facial points on healthy subjects and hemiplegia patients, however it was discovered that on points on the upper extremities the readings on the affected side were significantly lower than those of healthy subjects or those on the healthy side, moreover readings on affected sides in which numbness was reported were significantly lower than on the affected sides in cases in which no numbness was reported.
Results upon administering SG insertion to above cases in which there was reported numbness and measuring sutaneous surface temperatures periodically revealed that the difference in temperature 15 minutes after operations decreased slightly with a tendency to become greater than before operations 2 hours afterward. Also the interesting observation that the correlation of reciprocity of the 6 points varied acording to SG insertion, was made.

Objective: The need for tailoring ovarian cancer treatments to individual patients is increasing. This study aimed to evaluate the prognostic value of pretreatment laboratory test data for predicting the response and survival outcomes of platinumbased chemotherapy in ovarian cancer. Methods: We enrolled 270 patients with ovarian cancer diagnosed at the Kyoto Medical Center (n=120; group A) and Kyoto University (n=150; group B). Data on 9 blood parameters (neutrophil to lymphocyte ratio [NLR], platelet to lymphocyte rate [PLR], C-reactive protein, lactate dehydrogenase [LDH], glucose, total cholesterol, high-density lipoprotein [HDL], low-density lipoprotein, and triglyceride levels), cancer pathology, cancer stage, cytoreduction outcomes, serum cancer antigen 125 levels, platinum-free interval (PFI), disease-free survival (DFS), and overall survival were assessed retrospectively. Results: NLR, PLR, LDH, and HDL were significantly different in advanced stage patients (P<0.001, <0.001, 0.029, and <0.001, respectively). The Kaplan-Meier curves revealed that high LDH level (≥250 U/L) was associated with reduced PFI (P=0.037 and 0.012) and DFS (P=0.007 and 0.002) in groups A and B, respectively. High NLR (≥4) was associated with reduced DFS in both groups (P=0.036 and 0.005, respectively). LDH showed higher area under the curve (AUC) values in predicting platinum resistance with a PFI of less than 6 months and 12 months (AUC=0.606 and 0.646, respectively) than NLR. In the multivariate analysis, LDH remained significant (P=0.019) after adjusting for the 9 blood parameters. Conclusion Serum LDH level may possibly predict platinum resistance and prognosis in ovarian cancer and may be useful when developing precision medicine for individual patients.

Objective: The need for tailoring ovarian cancer treatments to individual patients is increasing. This study aimed to evaluate the prognostic value of pretreatment laboratory test data for predicting the response and survival outcomes of platinumbased chemotherapy in ovarian cancer. Methods: We enrolled 270 patients with ovarian cancer diagnosed at the Kyoto Medical Center (n=120; group A) and Kyoto University (n=150; group B). Data on 9 blood parameters (neutrophil to lymphocyte ratio [NLR], platelet to lymphocyte rate [PLR], C-reactive protein, lactate dehydrogenase [LDH], glucose, total cholesterol, high-density lipoprotein [HDL], low-density lipoprotein, and triglyceride levels), cancer pathology, cancer stage, cytoreduction outcomes, serum cancer antigen 125 levels, platinum-free interval (PFI), disease-free survival (DFS), and overall survival were assessed retrospectively. Results: NLR, PLR, LDH, and HDL were significantly different in advanced stage patients (P<0.001, <0.001, 0.029, and <0.001, respectively). The Kaplan-Meier curves revealed that high LDH level (≥250 U/L) was associated with reduced PFI (P=0.037 and 0.012) and DFS (P=0.007 and 0.002) in groups A and B, respectively. High NLR (≥4) was associated with reduced DFS in both groups (P=0.036 and 0.005, respectively). LDH showed higher area under the curve (AUC) values in predicting platinum resistance with a PFI of less than 6 months and 12 months (AUC=0.606 and 0.646, respectively) than NLR. In the multivariate analysis, LDH remained significant (P=0.019) after adjusting for the 9 blood parameters. Conclusion Serum LDH level may possibly predict platinum resistance and prognosis in ovarian cancer and may be useful when developing precision medicine for individual patients.